Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan‐Approved Humalog Insulin Lispro in Healthy Japanese Subjects-Reference-Cited by-同舟云学术

Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan‐Approved Humalog Insulin Lispro in Healthy Japanese Subjects

Published:2022-02-14 Issue:6 Volume:11 Page:754-760
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Shiramoto Masanari¹,Yoshihara Tatsuya¹,Schmider Wolfgang²,Takahashi Yoshinori³,Nowotny Irene²,Kajiwara Miyuki³,Muto Hideya³

Affiliation:

1. SOUSEIKAI Hakata Clinic Fukuoka Japan

2. Sanofi‐Aventis Deutschland GmbH Frankfurt Germany

3. Sanofi K.K. Tokyo Japan

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1068

Reference12 articles.

1. Insulin Lispro

3. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine—SORELLA 1 Study

4. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study

5. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments;Pharmaceutical Medicine;2024-04-29

2. New Insulins, Biosimilars, and Insulin Therapy;Diabetes Technology & Therapeutics;2023-02-01